Literature DB >> 32010565

Circ-ZKSCAN1 regulates FAM83A expression and inactivates MAPK signaling by targeting miR-330-5p to promote non-small cell lung cancer progression.

Yuanyong Wang1,2, Rongjian Xu1, Dongyang Zhang1, Tong Lu1,2, Wanpeng Yu2,3, Yang Wo1, Ao Liu1, Tianyi Sui1, Jian Cui1, Yi Qin1, Yanting Dong1,2, Xiaoliang Leng1, Dezhi Kong1, Wenxing Du1, Zhangfeng Huang1, Wenhao Su1, Tianxiang Yuan1, Xiao Sun1, Jianxun Wang2,3, Wenjie Jiao1.   

Abstract

BACKGROUND: Circular RNAs (circRNAs) belong to a new type of endogenous non-coding RNA and plays a key role in carcinogenesis. Circ-ZKSCAN1 (hsa_circ_0001727) has been proven to be a tumor-dependent circRNA. However, its role in non-small cell lung cancer (NSCLC) has been underreported.
METHODS: The expression patterns of circ-ZKSCAN1 were determined using qRT-PCR in NSCLC samples and cell lines. Cell proliferation was examined utilizing the CCK-8 assay. Cell migration and invasion were evaluated using the Transwell assay. The combination of circ-ZKSCAN1 and miR-330-5p in NSCLC cells was analyzed by RNA pull-down and luciferase reporter assay. We used the bioinformatics software circbank, CircInteractome, TargetScan and Miranda to predict circRNA-miRNA and miRNA-mRNA interactions.
RESULTS: Our results showed that circ-ZKSCAN1 was significantly up-regulated in NSCLC, closely related to malignant characteristics and poor prognosis, and clinically related to tumor size and clinical stage. Subsequent experiments showed that circ-ZKSCAN1 could inhibit the growth of NSCLC cells in vitro and in vivo. Importantly, circ-ZKSCAN1 can act as a sponge of carcinogenic miR-330-5p to increase the expression of FAM83A, resulting in the inhibition of MAPK signal transduction pathway, thus promoting the progress of NSCLC. Interestingly, the increase in FAM83A expression caused by circ-ZKSCAN1 overexpression could in turn promote the expression of circ-ZKSCAN1.
CONCLUSIONS: Circ-ZKSCAN1 is a key positive regulator of NSCLC, and clarifies the potential molecular mechanism of the new circ-ZKSCAN1/miR-330-5p/FAM83A feedback loop in promoting the progress of NSCLC. 2019 Translational Lung Cancer Research. All rights reserved.

Entities:  

Keywords:  FAM83A; Non-small cell lung cancer (NSCLC); circ-ZKSCAN1; miR-330-5p; prognosis

Year:  2019        PMID: 32010565      PMCID: PMC6976350          DOI: 10.21037/tlcr.2019.11.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  30 in total

1.  Systematic characterization of the zinc-finger-containing proteins in the mouse transcriptome.

Authors:  Timothy Ravasi; Thomas Huber; Mihaela Zavolan; Alistair Forrest; Terry Gaasterland; Sean Grimmond; David A Hume
Journal:  Genome Res       Date:  2003-06       Impact factor: 9.043

Review 2.  Regulation of circRNA biogenesis.

Authors:  Ling-Ling Chen; Li Yang
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

3.  MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma.

Authors:  Rajesh Pradhan; Gautam Singhvi; Sunil Kumar Dubey; Gaurav Gupta; Kamal Dua
Journal:  Future Med Chem       Date:  2019-04-17       Impact factor: 3.808

Review 4.  Early-Stage NSCLC: Advances in Thoracic Oncology 2018.

Authors:  Raymond U Osarogiagbon; Giulia Veronesi; Wentao Fang; Simon Ekman; Kenichi Suda; Joachim G Aerts; Jessica Donington
Journal:  J Thorac Oncol       Date:  2019-03-07       Impact factor: 15.609

5.  Circular RNA circ-FOXM1 facilitates cell progression as ceRNA to target PPDPF and MACC1 by sponging miR-1304-5p in non-small cell lung cancer.

Authors:  Guohua Liu; Hanbing Shi; Liling Deng; Hongyan Zheng; Weili Kong; Xiaoqiang Wen; Hongxia Bi
Journal:  Biochem Biophys Res Commun       Date:  2019-04-04       Impact factor: 3.575

6.  Natural RNA circles function as efficient microRNA sponges.

Authors:  Thomas B Hansen; Trine I Jensen; Bettina H Clausen; Jesper B Bramsen; Bente Finsen; Christian K Damgaard; Jørgen Kjems
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

7.  ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways.

Authors:  Zhicheng Yao; Jingyan Luo; Kunpeng Hu; Jizong Lin; He Huang; Qiangliang Wang; Peng Zhang; Zhiyong Xiong; Chonghua He; Zejian Huang; Bo Liu; Yang Yang
Journal:  Mol Oncol       Date:  2017-03-17       Impact factor: 6.603

8.  The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression.

Authors:  Rui Yang; Lei Xing; Xiaying Zheng; Yan Sun; Xiaosong Wang; Junxia Chen
Journal:  Mol Cancer       Date:  2019-01-08       Impact factor: 41.444

9.  Circular RNAs negatively regulate cancer stem cells by physically binding FMRP against CCAR1 complex in hepatocellular carcinoma.

Authors:  Yan-Jing Zhu; Bo Zheng; Gui-Juan Luo; Xu-Kai Ma; Xin-Yuan Lu; Xi-Meng Lin; Shuai Yang; Qing Zhao; Tong Wu; Zhi-Xuan Li; Xiao-Long Liu; Rui Wu; Jing-Feng Liu; Yang Ge; Li Yang; Hong-Yang Wang; Lei Chen
Journal:  Theranostics       Date:  2019-05-26       Impact factor: 11.556

10.  Evaluating the bias of circRNA predictions from total RNA-Seq data.

Authors:  Jinzeng Wang; Kang Liu; Ya Liu; Qi Lv; Fan Zhang; Haiyun Wang
Journal:  Oncotarget       Date:  2017-12-06
View more
  28 in total

1.  Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint.

Authors:  Jie Lei; Jianfei Zhu; Bengang Hui; Chenghui Jia; Xiaolong Yan; Tao Jiang; Xiaoping Wang
Journal:  Cancer Immunol Immunother       Date:  2022-06-24       Impact factor: 6.968

2.  Circular RNA EPB41 expression predicts unfavorable prognoses in NSCLC by regulating miR-486-3p/eIF5A axis-mediated stemness.

Authors:  Mingming Jin; Xiyu Liu; Yue Wu; Yuqing Lou; Xue Li; Gang Huang
Journal:  Cancer Cell Int       Date:  2022-06-20       Impact factor: 6.429

3.  KLF2-induced circZKSCAN1 potentiates the tumorigenic properties of clear cell renal cell carcinoma by targeting the miR-1294/PIM1 axis.

Authors:  Mingzi Li; Mingxun Zhang; Muling Chen; Jiantao Xiao; Xingyu Mu; Jingtao Peng; Jie Fan
Journal:  Cell Cycle       Date:  2022-03-14       Impact factor: 5.173

4.  CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC).

Authors:  Yongsheng Zhao; Renyan Zheng; Jian Chen; Dong Ning
Journal:  Cancer Cell Int       Date:  2020-07-06       Impact factor: 5.722

5.  Knockdown of circPRKCA Restrained Cell Growth, Migration, and Invasion of NSCLC Cells Both in vitro and in vivo via Regulating miR-330-5p/PDK1/AKT Pathway.

Authors:  Lanxiang Bai; Xiaonu Peng; Ruimei Sun
Journal:  Cancer Manag Res       Date:  2020-09-25       Impact factor: 3.989

6.  Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.

Authors:  Yanyao Deng; Hongwei Zhu; Le Xiao; Chao Liu; Xiangrui Meng
Journal:  Aging (Albany NY)       Date:  2020-12-09       Impact factor: 5.682

7.  Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression.

Authors:  Yuanyong Wang; Yang Wo; Tong Lu; Xiao Sun; Ao Liu; Yanting Dong; Wenxing Du; Wenhao Su; Zhangfeng Huang; Wenjie Jiao
Journal:  Transl Lung Cancer Res       Date:  2021-01

8.  Circ_0001821 knockdown suppresses growth, metastasis, and TAX resistance of non-small-cell lung cancer cells by regulating the miR-526b-5p/GRK5 axis.

Authors:  Ying Liu; Changchao Li; Huiqun Liu; Jing Wang
Journal:  Pharmacol Res Perspect       Date:  2021-08

Review 9.  Circular RNAs regulate cancer-related signaling pathways and serve as potential diagnostic biomarkers for human cancers.

Authors:  Pranavi Garlapati; Jinjie Ling; Paul J Chiao; Jie Fu
Journal:  Cancer Cell Int       Date:  2021-06-23       Impact factor: 5.722

Review 10.  Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives.

Authors:  Huan-Huan Chen; Tie-Ning Zhang; Qi-Jun Wu; Xin-Mei Huang; Yu-Hong Zhao
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.